AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,612,453 | +3.5% | 132,603 | +6.9% | 0.00% | 0.0% |
| Q2 2023 | $1,557,478 | +33.3% | 124,003 | +17.7% | 0.00% | – |
| Q1 2023 | $1,168,198 | +39.2% | 105,338 | +53.3% | 0.00% | – |
| Q4 2022 | $839,181 | +273.0% | 68,729 | +218.1% | 0.00% | – |
| Q3 2022 | $225,000 | -65.2% | 21,609 | -64.2% | 0.00% | – |
| Q2 2022 | $647,000 | -74.9% | 60,305 | -77.9% | 0.00% | – |
| Q1 2022 | $2,580,000 | +25.8% | 272,444 | +53.4% | 0.00% | – |
| Q4 2021 | $2,051,000 | -23.1% | 177,615 | -36.4% | 0.00% | – |
| Q3 2021 | $2,667,000 | +7.2% | 279,221 | +8.2% | 0.00% | -100.0% |
| Q2 2021 | $2,488,000 | -38.9% | 258,085 | -37.4% | 0.00% | -66.7% |
| Q1 2021 | $4,074,000 | -11.5% | 412,362 | +106.8% | 0.00% | +50.0% |
| Q4 2020 | $4,603,000 | +33.5% | 199,371 | -18.3% | 0.00% | 0.0% |
| Q3 2020 | $3,447,000 | +7.0% | 244,123 | +14.2% | 0.00% | 0.0% |
| Q2 2020 | $3,223,000 | +58.5% | 213,726 | -2.9% | 0.00% | 0.0% |
| Q1 2020 | $2,034,000 | +164.2% | 220,136 | +178.3% | 0.00% | +100.0% |
| Q4 2019 | $770,000 | +43.1% | 79,100 | +83.6% | 0.00% | 0.0% |
| Q2 2019 | $538,000 | +6.1% | 43,078 | +15.6% | 0.00% | 0.0% |
| Q1 2019 | $507,000 | +42.8% | 37,266 | +0.6% | 0.00% | 0.0% |
| Q4 2018 | $355,000 | -71.8% | 37,034 | -64.4% | 0.00% | -66.7% |
| Q3 2018 | $1,258,000 | +54.0% | 104,045 | +99.1% | 0.00% | +200.0% |
| Q2 2018 | $817,000 | -58.3% | 52,247 | -59.8% | 0.00% | -80.0% |
| Q1 2018 | $1,957,000 | +86.9% | 130,118 | +78.8% | 0.01% | +66.7% |
| Q4 2017 | $1,047,000 | -27.7% | 72,755 | -24.2% | 0.00% | -40.0% |
| Q3 2017 | $1,448,000 | +83.3% | 96,007 | +22.4% | 0.01% | +66.7% |
| Q2 2017 | $790,000 | +109.5% | 78,452 | +48.4% | 0.00% | +50.0% |
| Q1 2017 | $377,000 | +16.0% | 52,855 | -19.1% | 0.00% | 0.0% |
| Q4 2016 | $325,000 | +371.0% | 65,332 | +418.6% | 0.00% | – |
| Q2 2016 | $69,000 | -93.3% | 12,597 | -89.6% | 0.00% | -100.0% |
| Q1 2016 | $1,026,000 | +37.3% | 121,466 | +57.8% | 0.01% | +50.0% |
| Q4 2015 | $747,000 | +281.1% | 76,967 | +449.8% | 0.00% | +300.0% |
| Q3 2015 | $196,000 | -84.7% | 14,000 | -84.5% | 0.00% | -88.9% |
| Q2 2015 | $1,278,000 | +92.8% | 90,308 | +48.2% | 0.01% | +80.0% |
| Q1 2015 | $663,000 | -55.5% | 60,928 | -86.3% | 0.01% | -73.7% |
| Q2 2014 | $1,490,000 | – | 446,057 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |